Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
- Citation:
- Leuk Lymphoma vol 50 (10) 1589-96
- Year:
- 2009
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- Received
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- 470
- Children:
- None
- Pharmas:
- Grants:
- CA31946
- Corr. Author:
- Authors:
- John C Byrd Bercedis L Peterson Kanti R Rai David Hurd Raymond Hohl Michael C Perry Jon Gockerman Sreenivasa Nattam Richard A Larson
- Networks:
- Study
- CALGB-19901
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Adult, Aged, Alemtuzumab, Anti-Infective Agents, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibodies, Neoplasm, Antigens, CD, Antigens, Neoplasm, Bone Marrow Diseases, CD52 Antigen, Cohort Studies, Cytomegalovirus Infections, Feasibility Studies, Female, Glycoproteins, Humans, Hypotension, Infusions, Intravenous, Injections, Subcutaneous, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Neoplasm Proteins, Survival Analysis, Vidarabine